McKesson raises forecasts for annual profits in terms of plans to focus on high margin businesses
By Mrinalika Roy and Kamal Choudhury
(Reuters) -Mckesson (MCK) increased its profits on Tuesday, as the American drug distributor aims to focus on high margin companies such as cancer drugs to stimulate growth.
The Texas based company now expects the adjusted profit to varies between $ 38.05 and $ 38.55 per share for the year 2026, against its previous forecast of $ 37.10 to $ 37.90.
It also raised its objective of growth in long -term adjusted profits at 13% to 16%, from a previous beach from 12% to 14%.
McKesson’s shares increased by around 6% after the announcement.
The solid operational history of the company and disciplined execution would offer “a significant impact through the health care ecosystem,” said CEO Brian Tyler.
McKesson announced last week a reorganization of its activities, including a newly defined unit of oncology and multi -room.
The segment, which includes care against cancer, retina services and the distribution of specialized drugs, is expected to increase by 13% to 16% per year, the fastest among the company’s divisions.
Its segment of prescription technology solutions, which helps biopharmacy companies with patient access and membership tools, targets annual growth from 10% to 13%.
The North American pharmaceutical segment, which includes traditional drug distribution, is expected to increase from 5% to 8%.
Analysts described the positive signal update before McKesson’s investor day which later Tuesday.
“Overall, we consider this as a positive indicator for the future capacity of the growth of society,” said Leerink Partners analysts in a note.
McKesson has expanded its presence in oncology through acquisitions and partnerships, in particular the acquisition of approximately 2.49 billion dollars of majority participation in Core Ventures, a commercial service company linked to Florida cancer specialists.
“This morning’s announcement is a positive vs wait,” said Elizabeth Anderson, Evercore ISI analyst.
She added that the current operating environment would be developed during investor day, given the recent concerns of investors concerning the prices of medicines.
McKesson said that he also planned to update investors on the planned separation of his unit of medical-surgical solutions.
(Report by Mrinalika Roy and Kamal Choudhury in Bengaluru; edition by Shreya Biswas)
